Anzeige
Mehr »
Login
Sonntag, 07.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Bam Bam Resources und die Mega-Kupferlagerstätte in Teslas Hinterhof!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1WZEV ISIN: SE0003943620 Ticker-Symbol: EN9 
Frankfurt
05.03.21
17:04 Uhr
1,350 Euro
-0,020
-1,46 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ENZYMATICA AB Chart 1 Jahr
5-Tage-Chart
ENZYMATICA AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,3301,38005.03.

Aktuelle News zur ENZYMATICA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.02.ENZYMATICA AB: Positive operating result and almost doubled sales for the fourth quarter7
11.02.Enzymatica comments on article in Dagens Medicin244STOCKHOLM, Feb. 11, 2021 /PRNewswire/ -- Dagens Medicin is critizing in an article on February 10, 2021 one of the clinical studies, the so called ColdPrev I, which is part of the clinical...
► Artikel lesen
11.02.ENZYMATICA AB: Enzymatica comments on article in Dagens Medicin2
ENZYMATICA Aktie jetzt für 0€ handeln
21.01.Recipharm Signs Manufacturing Deal with Enzymatica7
15.01.New strategic recruitments and organizational changes at Enzymatica186STOCKHOLM, Jan. 15, 2021 /PRNewswire/ -- To support Enzymatica's growth journey, Enzymatica has hired Malin Richter to serve as Director Operations and Kristoffer Ahlerup as Director Commercial...
► Artikel lesen
15.01.ENZYMATICA AB: New strategic recruitments and organizational changes at Enzymatica1
13.01.RECIPHARM AB: Recipharm signs manufacturing agreement with Enzymatica4
09.12.20ENZYMATICA AB: STADA agreement extended for the Nordic Region9
12.11.20Enzymatica enters agreement with MS Pharma for MENA253STOCKHOLM, Nov. 12, 2020 /PRNewswire/ -- Enzymatica and MS Pharma, with headquarters in Amman, Jordan, have entered an agreement for marketing, distribution and sales of Enzymatica's common...
► Artikel lesen
12.11.20ENZYMATICA AB: Enzymatica enters agreement with MS Pharma for MENA3
03.11.20Enzymatica - Continued strong sales increase and positive cash flow in third quarter339STOCKHOLM, Nov. 3, 2020 /PRNewswire/ -- Q3 Net sales reached SEK 28.3 (19.5) million. Result after tax came in at SEK -1.9 (-7.7) million. Earnings...
► Artikel lesen
03.11.20ENZYMATICA AB: Continued strong sales increase and positive cash flow in third quarter2
21.10.20Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme471STOCKHOLM, Oct. 21, 2020 /PRNewswire/ -- Enzymatica and Sanofi Consumer Health Care, part of the French pharmaceutical group Sanofi, have entered an agreement for marketing, distribution...
► Artikel lesen
21.10.20ENZYMATICA AB: Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme7
13.10.20Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries389Enzymatica has licensed to STADA exclusive rights to market and sell the common cold spray ViruProtect (ColdZyme) in Russia, Poland, Ukraine and 11 further countries in the CIS and Central...
► Artikel lesen
13.10.20ENZYMATICA AB: Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries10
07.10.20ENZYMATICA AB: ColdZyme launched in Israel3
28.09.20The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica's in vitro study on SARS-CoV-2312STOCKHOLM, Sept. 28, 2020 /PRNewswire/ -- On July 20 Enzymatica announced the preliminary results from the in vitro study, showing that the mouth spray ColdZyme deactivates SARS-CoV-2, the...
► Artikel lesen
28.09.20ENZYMATICA AB: The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica's in vitro study on SARS-CoV-21
23.09.20ENZYMATICA AB: New patents approved for ColdZyme in Japan and Russia-
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1